This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Acute myelogenous leukemia (AML)	Notch 1 (NOTCH1)	Two studies <i>in vitro</i> and in mice suggest NOTCH pathway activation could help treat AML. In human AML samples and in a mouse model for the cancer, NOTCH-mediated activation of target genes and NOTCH1 mRNA were lower than those in samples from healthy controls. In AML mouse models, increasing NOTCH pathway signaling led to greater cancer cell apoptosis, differentiation and cell cycle arrest than control treatments. Next steps include developing a stable peptide or small molecule agonist of the NOTCH pathway. SciBX 6(8); doi:10.1038/scibx.2013.186 Published online Feb. 28, 2013	Patent and licensing status unavailable for findings in first study Findings in second study unpatented; available for licensing	Lobry, C. <i>et al. J. Exp. Med.</i> ; published online Jan. 28, 2013; doi:10.1084/jem.20121484 Contact: Iannis Aifantis, New York University School of Medicine, New York, N.Y. e-mail: iannis.aifantis@nyumc.org Contact: Camille Lobry, same affiliation as above e-mail: camille.lobry@nyumc.org Kannan, S. <i>et al. J. Exp. Med.</i> ; published online Jan. 28, 2013; doi:10.1084/jem.20121527 Contact: Patrick A. Zweidler-McKay, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: pzweidler@mdanderson.org